Experimental Therapeutics of Anti-Cancer Agents with Phase I Emphasis

Grants and Contracts Details


UM1 Subcontract with the Markey Cancer Center at the University of Kentucky Roles and areas of responsibility of the PI’s – Grever/OSU and DiPaola/UK Serve on NCI’s IDB Steering Committee Overall scientific and financial responsibility for the Phase I program Overseeing the ETCTN clinical trials and patient accruals Joint decision authority regarding selection of projects to pursue Assign opportunities to investigators Develop concepts and submit proposals for consideration to the IDB Plan for teamwork Drs. DiPaola and Arnold will “attend” weekly OSU meetings (by phone) Additional leadership meetings will also be by phone (bi-weekly) Meeting twice annually in person
Effective start/end date4/1/162/28/18


  • Ohio State University: $81,109.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.